CK LIFE SCIENCES INT'L., (HOLDINGS) INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.345 HKD | +1.47% |
|
+2.99% | -44.35% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 3,508 | 8,362 | 8,458 | 7,112 | 7,593 | 5,959 |
| Enterprise Value (EV) 1 | 7,540 | 13,279 | 13,677 | 12,423 | 12,835 | 11,214 |
| P/E ratio | 13.3 x | 46 x | 67.7 x | 43.8 x | 57.5 x | 346 x |
| Yield | 2.74% | 1.15% | 1.14% | 1.35% | 1.01% | - |
| Capitalization / Revenue | 0.67 x | 1.68 x | 1.71 x | 1.32 x | 1.44 x | 1.12 x |
| EV / Revenue | 1.44 x | 2.67 x | 2.77 x | 2.3 x | 2.43 x | 2.11 x |
| EV / EBITDA | 14.5 x | 32.1 x | 60.4 x | 31 x | 32.6 x | 29.5 x |
| EV / FCF | -68.5 x | -157 x | -272 x | 113 x | 142 x | 195 x |
| FCF Yield | -1.46% | -0.64% | -0.37% | 0.88% | 0.7% | 0.51% |
| Price to Book | 0.82 x | 2 x | 1.79 x | 1.58 x | 1.83 x | 1.42 x |
| Nbr of stocks (in thousands) | 9,611,073 | 9,611,073 | 9,611,073 | 9,611,073 | 9,611,073 | 9,611,073 |
| Reference price 2 | 0.3650 | 0.8700 | 0.8800 | 0.7400 | 0.7900 | 0.6200 |
| Announcement Date | 4/3/19 | 4/2/20 | 4/12/21 | 4/8/22 | 4/13/23 | 4/18/24 |
1HKD in Million2HKD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 5,233 | 4,967 | 4,943 | 5,402 | 5,276 | 5,323 |
| EBITDA 1 | 521.4 | 413.3 | 226.4 | 400.3 | 393.8 | 380.7 |
| EBIT 1 | 383.1 | 279.4 | 84.75 | 236.6 | 239.9 | 223.8 |
| Operating Margin | 7.32% | 5.63% | 1.71% | 4.38% | 4.55% | 4.21% |
| Earnings before Tax (EBT) 1 | 421.2 | 217.4 | 119.1 | 238.2 | 204.9 | 68.58 |
| Net income 1 | 263 | 181.7 | 125.2 | 162.8 | 132 | 17.25 |
| Net margin | 5.03% | 3.66% | 2.53% | 3.01% | 2.5% | 0.32% |
| EPS 2 | 0.0274 | 0.0189 | 0.0130 | 0.0169 | 0.0137 | 0.001794 |
| Free Cash Flow 1 | -110.1 | -84.45 | -50.22 | 109.8 | 90.23 | 57.61 |
| FCF margin | -2.1% | -1.7% | -1.02% | 2.03% | 1.71% | 1.08% |
| FCF Conversion (EBITDA) | - | - | - | 27.42% | 22.91% | 15.13% |
| FCF Conversion (Net income) | - | - | - | 67.43% | 68.38% | 333.97% |
| Dividend per Share 2 | 0.0100 | 0.0100 | 0.0100 | 0.0100 | 0.008000 | - |
| Announcement Date | 4/3/19 | 4/2/20 | 4/12/21 | 4/8/22 | 4/13/23 | 4/18/24 |
1HKD in Million2HKD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 4,032 | 4,917 | 5,219 | 5,311 | 5,242 | 5,255 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 7.732 x | 11.9 x | 23.06 x | 13.26 x | 13.31 x | 13.8 x |
| Free Cash Flow 1 | -110 | -84.5 | -50.2 | 110 | 90.2 | 57.6 |
| ROE (net income / shareholders' equity) | 6.55% | 4.42% | 2.82% | 3.53% | 3.05% | 0.41% |
| ROA (Net income/ Total Assets) | 2.28% | 1.65% | 0.47% | 1.25% | 1.3% | 1.24% |
| Assets 1 | 11,545 | 11,006 | 26,828 | 13,051 | 10,120 | 1,388 |
| Book Value Per Share 2 | 0.4400 | 0.4300 | 0.4900 | 0.4700 | 0.4300 | 0.4400 |
| Cash Flow per Share 2 | 0.0800 | 0.0700 | 0.1000 | 0.0900 | 0.0700 | 0.0700 |
| Capex 1 | 194 | 164 | 335 | 216 | 216 | 288 |
| Capex / Sales | 3.71% | 3.3% | 6.79% | 4% | 4.09% | 5.4% |
| Announcement Date | 4/3/19 | 4/2/20 | 4/12/21 | 4/8/22 | 4/13/23 | 4/18/24 |
1HKD in Million2HKD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -44.35% | 424M | |
| +8.20% | 7.78B | |
| +0.34% | 7.38B | |
| +10.20% | 6.52B | |
| -8.10% | 3.67B | |
| -13.13% | 3.44B | |
| -14.57% | 1.17B | |
| +8.34% | 934M | |
| -42.27% | 879M | |
| -18.90% | 836M |
- Stock Market
- Equities
- 775 Stock
- Financials CK Life Sciences Int'l., (Holdings) Inc.
